Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 7;72(12):1998–2004. doi: 10.1002/art.41425

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020, American College of Rheumatology

This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.

PMC Copyright notice

Dynamic changes in the levels of antiphospholipid antibodies (aPLs) during coronavirus disease 2019 (COVID‐19) infection in 6 critically ill patients. A, Medium levels of IgG anti–β₂‐glycoprotein I (aβ₂GP1) persisted after a transient appearance of IgA anti‐β₂GPI + IgA anticardiolipin antibodies (aCLs) in patient 1. B, Medium levels of IgA anti‐β₂GPI + IgA aCLs persisted after a transient appearance of IgG anti‐β₂GPI in patient 2 (left) and patient 3 (right). C, Transient appearance of aPLs in patient 4 (left) and patient 5 (right) was observed. D, High levels of IgA aCL + IgA anti‐β₂GPI + IgG anti‐β₂GPI persisted in patient 6. CU = chemiluminescent units.